Cholestane compound or salt thereof, disinfectant, preparation method therefor and use thereof
By preparing cholesterol compounds and their salts as active ingredients in disinfectants, the problem of existing disinfectants being unable to kill a variety of pathogens in a short time has been solved, achieving broad-spectrum and highly efficient disinfection effects, especially highly efficient killing of bacterial spores. Furthermore, the use of pH value and co-solvents has been optimized to improve safety.
Patent Information
- Application Number
- PCT/CN2026/070958
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-01-06
- Publication Date
- 2026-11-19
AI Technical Summary
Existing disinfectants are insufficient to meet the requirements of broad-spectrum and highly effective killing of a variety of pathogens in a short period of time, especially their poor killing effect on bacterial spores. Furthermore, there are problems such as large differences in activity between structural analogs and the fact that the influence of pH on the killing effect is not fully utilized.
Using cholesterol compounds or their salts as active ingredients in disinfectants, compounds 1, 2, and 4 and their salts are prepared through a specific synthetic route, and disinfectants are formulated under pH ≥ 7.0 conditions. Combined with solubilizers and pH adjusters, a broad-spectrum and highly effective disinfectant product is formed.
Compounds 1, 2, and 4, and their salts, can effectively kill Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans within 1 minute, meeting the requirements of national disinfectant technical specifications. They also exhibit highly effective disinfection against spores and have higher oral gavage safety.
Smart Images

Figure CN2026070958_19112026_PF_FP_ABST
Abstract
Description
A cholesterol compound or its salt, a disinfectant, and its preparation method and application. Technical Field
[0001] This invention belongs to the field of medical and health technology, specifically relating to a cholesterol compound or its salt, a disinfectant, and its preparation method and application. Background Technology
[0002] Disinfectants are preparations used to kill pathogenic microorganisms on transmission vectors, rendering them harmless. Unlike antibiotics, their main role in disease prevention is to eliminate pathogenic microorganisms outside the human body, cutting off the transmission routes of infectious diseases to control them.
[0003] Based on their effectiveness, disinfectants can be categorized into high-efficiency disinfectants, intermediate-efficiency disinfectants, and low-efficiency disinfectants. High-efficiency disinfectants specifically refer to preparations that can kill all vegetative bacteria (including mycobacteria), viruses, fungi and their spores, and also have a certain killing effect on bacterial spores (pathogenic spores), achieving high-level disinfection requirements. Intermediate-efficiency disinfectants refer to preparations that can only kill microorganisms such as mycobacteria, fungi, viruses, and vegetative bacteria, achieving disinfection requirements. Low-efficiency disinfectants refer to preparations that can only kill vegetative bacteria and lipophilic viruses, achieving disinfection requirements.
[0004] Depending on the application scenario, disinfectants can be divided into hand disinfection, skin and mucous membrane disinfection, air disinfection, medical device and supply disinfection, food (drinking) utensil disinfection, general item surface and fabric disinfection, drinking water and swimming pool water disinfection, fruit and vegetable disinfection, etc.
[0005] For disinfectants used in different application scenarios, their efficacy must be tested according to national disinfectant technical requirements. For example, disinfectants applied to hands must be tested against at least Staphylococcus aureus (Gram-positive bacteria), Escherichia coli (Gram-negative bacteria), Pseudomonas aeruginosa (Gram-negative bacteria), and Candida albicans (fungus). For high-level disinfection of medical devices and supplies, testing for Bacillus subtilis var. niger spores is required.
[0006] According to national technical specifications for disinfectants, qualified disinfectants must have a sufficiently strong killing effect on bacteria or spores within a specified killing time. Killing time, or KT for short, is used in the identification of biological indicator resistance and refers to the shortest time (in minutes) required for all samples of the test indicator to remain sterile after being treated with the bactericidal agent. Under the condition of achieving the same sterilization effect, the shorter the killing time, the better. According to the national technical standard for hand disinfectants, GB27950-2020dz, qualified hand disinfectants, at the usage concentration, must simultaneously meet the following killing indicators within one minute: a logarithmic limit of ≥5 for Staphylococcus aureus (Gram-positive bacteria), Escherichia coli (Gram-negative bacteria), and Pseudomonas aeruginosa (Gram-negative bacteria) (determined by suspension method, the same below); and a logarithmic limit of ≥4 for Candida albicans (fungus). Qualified high-efficiency disinfectants for medical devices and supplies must meet the requirement of killing spores with a log number greater than or equal to 5 within the declared killing time (generally not exceeding 1 hour).
[0007] With the increasing use of various antibiotics and disinfectants in the environment and on the human body, bacteria and viruses are constantly mutating under the pressure of survival and evolution, posing an increasingly serious threat to humanity. Developing new disinfectants is of great significance for maintaining public health. An ideal new disinfectant should possess: sufficient human safety and environmental friendliness at low application concentrations; the shorter the better for killing bacteria; and broad-spectrum, highly effective killing properties.
[0008] Ceragenins are a class of compounds with antibacterial activity, and their antibacterial and anti-biofilm activities have been widely reported. For example, the literature (New β-Lactam Antibiotics and Ceragenins–A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of Pseudomonas aeruginosa. Infection and Drug Resistance. 2021:14 5681–5698) studied the minimum bactericidal concentration of CSA-13 (i.e., control compound 8 in this invention) against Pseudomonas aeruginosa. The above antibacterial or bactericidal activity tests all followed the drug susceptibility testing procedures specified by the European Committee for Antimicrobial Susceptibility Testing (EUCAST), with an interaction time of 18±2 hours between the compounds and bacteria. This is fundamentally different from the requirement for disinfectants to have a shorter kill time (in minutes). To date, there are no literature reports on the application of ceragenins in disinfection with a shorter kill time.
[0009] In fact, most compounds with good antibacterial activity, including approved antibiotics, fail to meet the technical specifications for disinfectants because they cannot rapidly and broadly kill pathogens. In conclusion, given the potential needs of public health, it is essential to research and develop safe, effective, and rapid-acting new disinfectants. Summary of the Invention
[0010] In order to solve the above-mentioned problems in the prior art, the purpose of this invention is to provide a cholesterol compound or its salt, a disinfectant, and its preparation method and application.
[0011] To achieve the above objectives, the present invention adopts the following technical solution:
[0012] This invention provides a cholesteric compound or a salt thereof, said cholesteric compound having a structure as shown in Formula I, Formula II or Formula III:
[0013] Furthermore, the salt is a hydrochloride, glucuronide, acetate, butyrate, or 1,5-naphthalenedisulfonate.
[0014] The present invention also provides a method for preparing the above-mentioned cholesterol compound, the method comprising the following steps:
[0015] (1) Bile acid compounds react with haloalkenes under alkaline conditions to give intermediate 1;
[0016] (2) Intermediate 1 reacts with an amine to give intermediate 2;
[0017] (3) Intermediate 2 undergoes a hydroboration-oxidation reaction to obtain intermediate 3;
[0018] (4) Intermediate 3 first reacts with a sulfonating agent to generate a sulfonate ester, and then reacts with a nucleophile under alkaline conditions to obtain intermediate 4;
[0019] (5) Intermediate 4 is hydrolyzed under acidic conditions and reacts with a reducing agent to obtain the cholesteric compound; wherein, when the cholic acid compound is allochedeoxycholic acid, intermediate 1 is... When the amine is octylamine, intermediate 2 is Intermediate 3 is Intermediate 4 is Cholesterol compounds are
[0020] When the bile acid compound is porcine deoxycholic acid, intermediate 1 is... When the amine is octylamine, intermediate 2 is Intermediate 3 is Intermediate 4 is Cholesterol compounds are
[0021] When the bile acid compound is porcine deoxycholic acid, intermediate 1 is... When the amine is laurylamine, intermediate 2 is Intermediate 3 is Intermediate 4 is Cholesterol compounds are
[0022] Further, the cholic acid compound mentioned in step (1) is allocodeoxycholic acid or porcine deoxycholic acid;
[0023] The amine mentioned in step (2) is R-NH2, where R is C 3~12 alkyl;
[0024] The borohydride-oxidizing agent mentioned in step (3) is 9-boronbicyclo[3.3.1]nonane and H2O2;
[0025] The sulfonating agent in step (4) is chloride methanesulfonate, and the nucleophile is bis(tert-butoxycarbonyl)amine;
[0026] The reducing agent in step (5) is borane.
[0027] Furthermore, the amine is octylamine or laurylamine.
[0028] The present invention also provides a disinfectant, which is a preparation made of the above-mentioned cholesteric compound or its salt, compound 6 or its salt, and compound 8 or its salt as active ingredients, and the disinfectant has a pH ≥ 7.0.
[0029] Furthermore, the pH of the disinfectant is 7.0 to 11.0.
[0030] Furthermore, the disinfectant also includes a solvent, a disinfectant-acceptable co-solvent, and a pH adjuster.
[0031] Furthermore, the solvent is water, the co-solvent is glycerol, and the pH adjuster is at least one of ethylenediaminetetraacetic acid tetrasodium, sodium metasilicate pentahydrate, sodium phosphate, and sodium carbonate.
[0032] Furthermore, the solvent is water, the co-solvent is glycerol, and the pH adjuster is sodium metasilicate pentahydrate.
[0033] The present invention also provides the application of the above-mentioned compounds or their salts or the above-mentioned disinfectants in the preparation of disinfection products for mucosal and skin disinfection, hand disinfection, foot disinfection, medical device and supply disinfection, fabric disinfection, food (drinking) utensil disinfection, drinking water and swimming pool water disinfection, and fruit and vegetable disinfection.
[0034] The present invention also provides the use of the above-mentioned compound or its salt or the above-mentioned disinfectant in the preparation of disinfectant products for killing at least one of bacteria, fungi and their spores or viruses.
[0035] Furthermore, the disinfectant product is a disinfectant product used to kill at least one of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Bacillus subtilis var. niger spores.
[0036] The present invention also provides a method for disinfecting mucous membranes and skin, hands, feet, medical devices and supplies, fabrics, food (drinking) utensils, drinking water and swimming pool water, fruits and vegetables using the above-mentioned compounds or their salts or the above-mentioned disinfectants.
[0037] The present invention has achieved the following beneficial effects:
[0038] 1. The closest disclosed prior art to this invention is Ceragenins, represented by compounds 6 and 8. Although various antibacterial activities have been reported in these compounds, their application as disinfectants has not yet been observed. Especially for hand disinfection, according to national technical specifications, it is required to simultaneously achieve a kill effect of 4 or 5 log values against Candida albicans, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa within 1 minute. Compounds 1, 2, 3, 4, 5, 6, 7, and 8 have similar structures but exhibit significantly different disinfection activities. As described in Experimental Example 2, at the same concentration, compounds 3, 5, and 7 did not demonstrate a satisfactory kill effect against Escherichia coli and Pseudomonas aeruginosa within 1 minute, with compound 7 showing the worst effect. Compounds 1, 2, 4, 6, and 8 can effectively kill Escherichia coli and Pseudomonas aeruginosa. However, in terms of killing Candida albicans and Staphylococcus aureus within 1 minute, as described in Experiments 3 and 5, under the same conditions, compounds 1 and 2 are the most effective and have significantly superior activity compared to compounds 6 and 8. Compound 4 also has a strong killing effect.
[0039] 2. This invention is the first to discover the disinfection pH effect of these compounds. As described in Experiment 3, even when the concentration of compounds 6 and 8 was increased to 20 mg / ml under weakly acidic conditions, they could not achieve a satisfactory 1-minute kill rate against Candida albicans and Staphylococcus aureus. As described in Experiments 4 and 5, pH ≥ 7 is a key condition for achieving a satisfactory 1-minute kill rate against Staphylococcus aureus and Candida albicans. The 1-minute kill rate against Escherichia coli and Pseudomonas aeruginosa was not sensitive to pH changes, indicating that the pH effect is significantly different for different bacterial species. Experiment 8 demonstrates that pH changes do not affect the antibacterial and bactericidal effects after 18 ± 2 hours. In summary, this pH effect is a first discovery of this invention, has never been reported in Ceragenins literature, and cannot be inspired by existing technologies; therefore, it is non-obvious.
[0040] 3. This invention has discovered that, in addition to the significant influence of pH, the structural differences of these compounds also affect their 1-minute killing effect. The results of Experimental Example 5 show that, although all belong to cholesterol structural analogues, differences in the position, number, and chirality of substituents all affect their activity. Under the same conditions, compounds 1 and 2 completely killed Staphylococcus aureus and Candida albicans, with significantly better effects than compounds 6 and 8. As mentioned in point 1, the 1-minute killing experiment on Escherichia coli and Pseudomonas aeruginosa also demonstrated the importance of structural differences, and this structure-activity relationship is unpredictable.
[0041] 4. In addition to the pH effect, this invention also discovers for the first time that the disinfectant co-solvent system has an extremely significant impact on the 1-minute killing effect.
[0042] 5. This invention also found that compounds 1 and 2 can achieve highly efficient disinfection effects against spores in a short time, meeting the national technical standards for highly efficient disinfection (Disinfection Technical Specifications (2002 edition)).
[0043] 6. Compounds 1 and 2 of the present invention have higher oral gavage safety compared to structural analog compound 8.
[0044] In summary, the novel compounds 1, 2, and 4 of this invention, as well as the known compounds 6 and 8 and their salts, especially the novel compounds 1, 2, and 4 and their salts, have broad application prospects in practical disinfection applications.
[0045] Obviously, based on the above description of the present invention, and according to common technical knowledge and conventional methods in the field, various other modifications, substitutions or alterations can be made without departing from the basic technical concept of the present invention.
[0046] The following detailed embodiments further illustrate the above-described content of the present invention. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above-described content of the present invention fall within the scope of the present invention. Attached Figure Description
[0047] Figure 1 shows the scatter plot, fitted curve, and curve equation of the dose logarithm and probability unit values of compound 1.
[0048] Figure 2 shows the scatter plot, fitted curve, and curve equation of the dose logarithm and probability unit values of compound 2.
[0049] Figure 3 shows the scatter plot, fitted curve, and curve equation of the dose logarithm and probability unit values of compound 8.
[0050] Figure 4: NMR spectrum of compound 1.
[0051] Figure 5: NMR spectrum of compound 1 hydrochloride.
[0052] Figure 6: NMR spectrum of compound 1 naphthalene disulfonate.
[0053] Figure 7: NMR spectrum of compound 2.
[0054] Figure 8: NMR spectrum of compound 2 hydrochloride. Detailed Implementation
[0055] The raw materials and equipment used in this invention are all known products, obtained by purchasing commercially available products.
[0056] The following experiments, where no temperature is specified, are reactions conducted under normal temperature conditions, which is room temperature, or 25±5℃.
[0057] Example 1: Preparation of Compound 1 and its salt
[0058] 1. Preparation of Compound 1
[0059] The synthetic route for compound 1 is as follows:
[0060] Step 1: Add 5g of allodeoxycholic acid (from Zhongshan Bailing Biotechnology Co., Ltd., CAS: 15357-34-3) to 50ml of tetrahydrofuran (THF), cool to -10~0℃, slowly add 8g of sodium hydride, stir for 2-3 minutes after the addition is complete, add 16g of allyl iodine (CAS: 556-56-9), stir for 2-3 minutes after the addition is complete, heat to 80℃, reflux for 4-5 hours, monitor the reaction to ensure completeness, cool the reaction solution, slowly pour it into water, extract three times with ethyl acetate (EA), combine the organic phases, concentrate and precipitate by silica gel column chromatography to obtain 5.1g of oil, which is compound B1.
[0061] Compound B1 has the following structure:
[0062] Step 2: Add 5g of intermediate compound B1 obtained in the previous step, 10g of O-benzotriazole-N,N,N',N'-tetramethylurea tetrafluoroborate (TBTU), 5g of N,N-diisopropylethylamine (DIPEA), and 2.5g of octylamine (CAS: 111-86-4) to 20ml of DMF, stir at room temperature for 1-2 hours, add water, extract twice with EA, wash the organic layer with dilute acid and saturated brine, dry and concentrate to obtain crude product, and precipitate 5.7g of intermediate by silica gel column chromatography to obtain compound C1.
[0063] Compound C1 has the following structure:
[0064] Step 3: Add 5g of intermediate compound C1 obtained in the previous step to a single-necked flask, add 25ml of THF, and add 35ml of 0.5M 9-boronbicyclo[3.3.1]nonane THF solution (9-BBN, CAS: 280-64-8) dropwise at low temperature. After nitrogen purging, stir at room temperature for 5 hours to obtain reaction solution 1. Add 10ml of 20% sodium hydroxide to another single-necked flask, cool to -10 to 0℃, and slowly add 10ml of 30% hydrogen peroxide. After the addition is complete, stir for 2 to 3 minutes to obtain reaction solution 2. Slowly add reaction solution 1 dropwise to reaction solution 2, controlling the temperature not to exceed 0℃. After the addition is complete, reflux the reaction for 3 to 5 hours, quench the reaction with sodium bisulfite aqueous solution, extract three times with EA, dry and concentrate, and then precipitate by silica gel column chromatography to obtain 4.1g of oil, which is compound D1.
[0065] Compound D1 has the following structure:
[0066] Steps 4 and 5: Add 4g of intermediate compound D1 from the previous step to DCM, cool to 0℃, add 2ml of triethylamine and 1.5g of chloromethanesulfonate, stir at room temperature for 1-2 hours, monitor for complete reaction, concentrate under reduced pressure, mix the residue with water, extract three times with EA, wash twice with sodium bicarbonate aqueous solution, and dry and concentrate the organic layer. Without purification, dissolve in an appropriate amount of DMF, add 6g of cesium carbonate and 4.5g of bis(tert-butyloxycarbonyl)amine (CAS: 51779-32-9), heat to 70-80℃ and react for 3-5 hours, monitor for complete reaction, add water, extract three times with EA, wash the organic layer with saturated brine, dry and concentrate, and column chromatography to obtain 3.5g of intermediate, which is compound E1.
[0067] Compound E1 has the following structure:
[0068] Steps 6 and 7: Add 2g of the above intermediate compound E1 to 20ml of methanol, cool to 0℃, add 2ml of acetyl chloride dropwise, stir overnight at room temperature, concentrate to dryness, add 15ml of THF, cool to -10~0℃, slowly add 20ml of borane (BH3, 1M) THF solution, react at 80℃ for 4~5 hours after the addition, add sodium bicarbonate aqueous solution, extract 3 times with DCM, dry and concentrate to obtain 0.9g of crude compound 1, the crude product is purified by preparative reversed-phase chromatography to obtain an oily substance with HPLC purity >98%, which is the target compound 1.
[0069] The NMR spectrum of compound 1 is shown in Figure 4. The characteristic hydrogen signal of NMR is as follows:
[0070] 1 H NMR (CD3OD, 400MHz) δ: 3.62 (dt, J = 9.1, 5.7Hz, 1H), 3.55-3.51 (m, 1H), 3.48-3.44 ( m,2H),3.21(dt,J=9.1,5.9Hz,1H),2.74(td,J=7.2,2.7Hz,4H),2.58-2.54(m,4H), 1.99-1.82((m,2H),1.80-1.66(m,5H),1.64-1.43(m,14H),1.43-1.16(m,16H),1.1 6-1.04(m,4H),0.95(d,J=6.4Hz,3H),0.93-0.86(m,4H),0.82(s,3H),0.67(s,3H);
[0071] Mass spectrometry data of compound 1:
[0072] ESI-MS m / z: 604.87 [M+1] + .
[0073] 2. Preparation of Compound 1 Hydrochloride
[0074] Compound 1, prepared according to the above method, was dissolved in methyl tert-butyl ether. Hydrochloric acid gas was passed through the solution, and a white solid precipitated out. The solution was then filtered to obtain the hydrochloride salt of compound 1.
[0075] The NMR spectrum of compound 1 hydrochloride is shown in Figure 5. The characteristic hydrogen signal of NMR is as follows:
[0076] 1HNMR (CD3OD, 400MHz) δ: 3.70 (dt, J-10.3, 5.5Hz, 1H), 3.59 (brs, 1H), 3.56-3. 49(m,2H),3.40-3.35(m,1H),3.29-3.22(m,2H),3.10-2.83(m,8H),2.00-1.8 6(m,6H),1.81-1.64(m,4H),1.60-1.43(m,12H),1.39-1.29(m,10H),1.24-1. 06(m,6H),0.97(d,J-6.4Hz,3H),0.95-0.86(m,3H),0.83(s,3H),0.69(s,3H);
[0077] Mass spectrometry data of compound 1 hydrochloride:
[0078] ESI-MS m / z: 604.87 [M+1] + .
[0079] 3. Preparation of compound 1 naphthalene disulfonate
[0080] Compound 1, prepared according to the method described above, was dissolved in methanol, and 2 equivalents of 1,5-naphthalenedisulfonic acid were added. A white solid gradually precipitated out, and after filtration and drying, its naphthalenedisulfonic acid salt was obtained. NMR data showed that compound 1 formed a salt with 1.5 molecules of 1,5-naphthalenedisulfonic acid.
[0081] The NMR spectrum of compound 1 naphthalene disulfonate is shown in Figure 6. Characteristic hydrogen signals from NMR:
[0082] 1 H NMR (d6-DMSO, 400MHz) δ: 8.87 (d, J = 8.6Hz, 3H), 8.24 (brs, 2H), 7.96 (d, J = 7.0Hz, 3 H),7.75-7.70(m,6H),7.44(dd,J=9.1,7.0Hz,3H),3.54-3.44(m,2H),3.36(t,J=6. 1Hz,2H),3.26(s,1H),3.18-3.14(m,1H),2.88-2.78(m,8H),1.90-1.87(m,1H),1. 82-1.28(m,17H),1.25-0.96(m,14H),0.90-0.82(m,6H),0.75(s,3H),0.61(s,3H);
[0083] Mass spectrometry data of compound 1 naphthalene disulfonate:
[0084] ESI-MS m / z: 604.87 [M+1] +286.95 [M-1] - (1,5-Naphthalenedisulfonic acid).
[0085] 4. Preparation of glucuronide, acetate, and butyrate of compound 1
[0086] Compound 1, prepared according to the above method, was dissolved in methyl tert-butyl ether, and at least 3 equivalents of glucuronic acid were added. A solid was precipitated under stirring, filtered, and dried to obtain glucuronide of compound 1.
[0087] ESI-MS m / z: 604.87 [M+1] + 193.05 [M-1] - (Glucuronic acid).
[0088] By replacing glucuronic acid with acetic acid and butyric acid, the acetate and butyrate of compound 1 can be obtained, respectively.
[0089] Example 2, Preparation of Compound 2 and its Salt
[0090] 1. Preparation of Compound 2
[0091] Compound 2 has the following structure:
[0092] Compound 2 was prepared by referring to the preparation method of compound 1 in Example 1, except that deoxycholic acid was replaced with commercially available porcine deoxycholic acid (CAS: 83-49-8).
[0093] The NMR spectrum of compound 2 is shown in Figure 7. The characteristic hydrogen signal of NMR is as follows:
[0094] 1 HNMR (CD3OD, 400MHz) δ: 3.65 (dt, J=11.8, 4.6Hz, 1H), 3.59-3.50 (m, 3H), 3.50-3.40 ( m,1H),3.30-3.18(m,2H),2.71(td,J=6.9Hz,4H),2.58-2.46(m,4H),2.05-1.98(m,1 H),1.94-1.78(m,2H),1.78-1.64((m,5H),1.52-1.38(m,6H),1.35-1.25(m,12H),1. 25-1.09(m,6H),0.95(d,J=6.4Hz,3H),0.92(s,3H),0.91-0.87(m,3H),0.68(s,3H);
[0095] Mass spectrometry data of compound 2:
[0096] ESI-MS m / z: 604.85 [M+1] + ;
[0097] 2. Preparation of compound 2 hydrochloride
[0098] Compound 2, prepared according to the above method, was dissolved in methyl tert-butyl ether, and hydrochloric acid gas was passed through it. A white solid precipitated out, and the solid was filtered and dried to obtain the hydrochloride salt of compound 2.
[0099] The NMR spectrum of compound 2 hydrochloride is shown in Figure 8. The characteristic hydrogen signal of NMR is as follows:
[0100] 1 HNMR (CD3OD, 400MHz) δ: 3.74-3.67(m,1H), 3.66-3.57(m,3H), 3.54-3.44(m,1H), 3.08-3.00(m,4H), 3.00-2.90(m,4H), 2.06-1.99(m ,1H),1.93-1.66((m,8H),1.50-1.27(m,17H),1.23-1.03(m,6H),0.98(d,J=6.3Hz,3H),0.93(s,3H),0.92-0.86(m,3H),0.69(s,3H);
[0101] 3. Preparation of compound 2-naphthalene disulfonate
[0102] Compound 2, prepared according to the method described above, was dissolved in tetrahydrofuran, and 2 equivalents of 1,5-naphthalenedisulfonic acid were added. A white solid gradually precipitated out, and after filtration and drying, its naphthalenedisulfonic acid salt was obtained. NMR data showed that compound 2 formed a salt with 1.5 molecules of 1,5-naphthalenedisulfonic acid.
[0103] Characteristic hydrogen signals from nuclear magnetic resonance of compound 2-naphthalene disulfonate:
[0104] 1 H NMR (CD3OD, 400MHz) δ: 9.02 (d, J = 8.6Hz, 4H), 8.22 (d, J = 7.2Hz, 4H), 7.60 (dd, J =8.7,7.2Hz,4H),3.76-3.68(m,1H),3.68-3.60(m,1H),3.59-3.50(m,3H),3.4 9-3.39(m,1H),3.05-2.86(m,6H),1.95-1.75(m,9H),1.74-1.62(m,8H),1.43- 1.28(m,17H),1.20-0.96(m,4H),1.34-0.89(m,7H),0.89(s,3H),0.61(s,3H);
[0105] Mass spectrometry data of compound 2-naphthalene disulfonate:
[0106] ESI-MS m / z: 604.85 [M+1] + , 287.12 [M-1] - (1,5-Naphthalenedisulfonic acid).
[0107] 4. Preparation of glucuronide, acetate, and butyrate of compound 2
[0108] Compound 2, prepared according to the above method, was dissolved in methyl tert-butyl ether, and at least 3 equivalents of glucuronic acid were added. A solid was precipitated under stirring, filtered, and dried to obtain glucuronide of compound 2.
[0109] ESI-MS m / z: 604.85 [M+1] + 193.05 [M-1] - (Glucuronic acid).
[0110] By replacing glucuronic acid with acetic acid and butyric acid, the acetate and butyrate of compound 2 can be obtained, respectively.
[0111] Example 3: Preparation of Compound 4 and its Salt
[0112] 1. Preparation of Compound 4
[0113] Compound 4 has the following structure:
[0114] The preparation method of compound 2 in Example 2 was followed, except that octylamine was replaced with laurylamine to obtain compound 4.
[0115] 2. Preparation of compound 4 hydrochloride
[0116] Compound 4, prepared according to the above method, was dissolved in methyl tert-butyl ether, and hydrochloric acid gas was passed through it. A white solid precipitated out, and the solid was filtered and dried to obtain the hydrochloride salt of compound 4.
[0117] Characteristic hydrogen signals from NMR of compound 4 hydrochloride:
[0118] 1H NMR (CD3OD, 400MHz) δ: 3.66-3.57(m,1H), 3.56-3.48(m,3H), 3.44-3.36(m,1H), 2.992.91(m,4H), 2.89-2.75(m,4H), 1.9 7-1.90(m,1H),1.86-1.55(m,10H),1.45-1.20(m,24H),1.17-0.96(m,10H),0.98-0.88(m,6H),0.84(s,3H),0.60(s,3H);
[0119] Mass spectrometry data of compound 4 hydrochloride:
[0120] ESI-MS m / z: 660.92 [M+1] +
[0121] Example 4: Preparation of high-level disinfectant
[0122] Dissolve 50g of glycerol and 15g of sodium metasilicate pentahydrate in 800g of pure water to obtain an aqueous solution; dissolve 50g of the compound hydrochloride in the above aqueous solution, and dilute to 1000ml with pure water to obtain a disinfectant with a concentration of 50mg / ml and a pH of 8.0. This disinfectant can be diluted with pure water at a ratio of 1:4 and can be used for high-level disinfection of medical devices and supplies.
[0123] Dissolve 50g of glycerol and 8-10g of sodium metasilicate pentahydrate in 850g of pure water to obtain an aqueous solution; dissolve 10g of the compound hydrochloride in the above aqueous solution and dilute to 1000ml with pure water to obtain a disinfectant with a concentration of 10mg / ml and a pH of 7.0-9.0. This disinfectant can be directly applied to the high-level disinfection of medical devices and supplies.
[0124] Among them, the hydrochloride compound is any one of the hydrochloride compounds 1, 2, and 4.
[0125] Example 5: Preparation of Hand Sanitizer
[0126] Dissolve 10g of glycerol and 0.3g of sodium metasilicate pentahydrate in 900g of water to obtain a solution. Dissolve 1g of the hydrochloride salt of compound 1 or compound 2 in the above aqueous solution and dilute to 1000ml with pure water to obtain a disinfectant with a concentration of 1mg / ml and a pH of 8.0. This disinfectant can be used for hand disinfection.
[0127] Example 6: Preparation of skin and mucous membrane disinfectant
[0128] Dissolve 10g of glycerol and 0.2-0.3g of sodium metasilicate pentahydrate in 900g of water to obtain a solution. Dissolve 0.5g of the hydrochloride salt of compound 1 or compound 2 in the above aqueous solution and dilute to 1000ml with pure water to obtain a disinfectant with a concentration of 0.5mg / ml and a pH of 7.0-8.0. This disinfectant can be used for skin and mucous membrane disinfection.
[0129] Example 7: Preparation of disinfectant for tableware, drinking water, fruits and vegetables
[0130] Dissolve 10g of glycerol and 0.1g of sodium metasilicate pentahydrate in 900g of water to obtain a solution. Dissolve 0.01g of the hydrochloride salt of compound 1 or compound 2 in the above aqueous solution, and then dilute to 1000ml with pure water to obtain a disinfectant with a concentration of 0.01mg / ml and a pH of 7.2. This disinfectant can be used for disinfecting tableware, drinking water, fruits, and vegetables. It can also be added to swimming pool water according to this preparation ratio for disinfection.
[0131] The following describes the preparation of the control compound and its salt.
[0132] Preparation of Comparative Example 1, Compound 3 and its salt
[0133] 1. Preparation of Compound 3
[0134] Compound 3 has the following structure:
[0135] The preparation method of compound 2 in Example 2 was followed, except that octylamine was replaced with propylamine to obtain compound 3.
[0136] 2. Preparation of compound 3 hydrochloride
[0137] Compound 3, prepared according to the above method, was dissolved in methyl tert-butyl ether, and hydrochloric acid gas was passed through it. A white solid precipitated out, and the solid was filtered and dried to obtain the hydrochloride salt of compound 3.
[0138] Characteristic hydrogen signals from NMR of compound 3 hydrochloride:
[0139] 1 H NMR (CD3OD, 400MHz) δ: 3.76-3.68(m,1H), 3.68-3.60(m,3H), 3.56-3.48(m,1H), 3.11-2.91(m,8H), 2.08-2.01(m,1H), 1.98-1.70(m, 14H),1.52-1.43(m,2H),1.41-1.26(m,16H),1.26-1.06(m,4H),1.00(d,J=6.4Hz,3H),0.96(s,3H),0.94-0.87(m,4H),0.72(s,3H);
[0140] Mass spectrometry data of compound 3 hydrochloride:
[0141] ESI-MS m / z: 535.23 [M+1] +
[0142] Preparation of Compound 5 (Comparative Example 2)
[0143] 1. Preparation of Compound 5
[0144] Compound 5 has the following structure:
[0145] Compound 5 was prepared by referring to the preparation method of compound 1 in Example 1, except that allodeoxycholic acid was replaced with commercially available ursodeoxycholic acid (CAS: 128-13-2).
[0146] 2. Preparation of compound 5 hydrochloride
[0147] Compound 5, prepared according to the above method, was dissolved in methyl tert-butyl ether, and hydrochloric acid gas was passed through it. A white solid precipitated out, and the solid was filtered and dried to obtain the hydrochloride salt of compound 5.
[0148] Characteristic hydrogen signals from nuclear magnetic resonance of compound 5 hydrochloride:
[0149] 1 HNMR(CD3OD,400MHz)δ: 3.68-3.58(m,3H),3.41-3.33(m,1H),3.27(m,1H),3.19-3.16(m,1H),3.07-2.86(m,8H),2.08-2.00(m,1H),1.94-1 .64(m,14H),1.54-1.44(m,8H),1.44-1.16(m,14H),1.16-1.02(m,2H ),0.99(d,J=6.4Hz,3H),0.96(s,3H),0.94-0.86(m,4H),0.70(s,3H);
[0150] Mass spectrometry data of compound 5 hydrochloride:
[0151] ESI-MS m / z: 605.10 [M+1] +
[0152] Preparation of Compound 6 (as in Example 3)
[0153] 1. Preparation of Compound 6
[0154] Compound 6 has the following structure:
[0155] Compound 6 was prepared by referring to the preparation method of compound 1 in Example 1, except that allodeoxycholic acid was replaced with commercially available chenodeoxycholic acid (CAS: 474-25-9).
[0156] 2. Preparation of Compound 6 Hydrochloride
[0157] Compound 6, prepared according to the above method, was dissolved in methyl tert-butyl ether, and hydrochloric acid gas was passed through it. A white solid precipitated out, and the solid was filtered and dried to obtain the hydrochloride salt of compound 6.
[0158] Characteristic hydrogen signals from NMR of compound 6 hydrochloride:
[0159] 1 HNMR (CD3OD, 400MHz) δ: 3.78 (dt, J=9.9, 5.4Hz, 1H), 3.65-3.56 (m, 2H), 3 .37-3.32(m,1H),3.23-3.13(m,2H),3.11-2.88(m,8H),2.16-1.97(m,1H) ,1.97-1.64(m,7H),1.64-1.43(m,3H),1.39-1.27(m,12H),1.24-1.10(m ,4H),0.98(d,J=6.4Hz,3H),0.94(s,3H),0.92-0.86(m,4H),0.69(s,3H);
[0160] Mass spectrometry data of compound 6 hydrochloride:
[0161] ESI-MS m / z: 605.10 [M+1] +
[0162] Preparation of Compound 7 (Comparative Example 4)
[0163] 1. Preparation of Compound 7
[0164] Compound 7 has the following structure:
[0165] Compound 7 was prepared by referring to the preparation method of compound 1 in Example 1, except that allodeoxycholic acid was replaced with commercially available lithocholic acid (CAS: 434-13-9).
[0166] 2. Preparation of Compound 7 Hydrochloride
[0167] Compound 7, prepared according to the above method, was dissolved in methyl tert-butyl ether, and hydrochloric acid gas was passed through it. A white solid precipitated out, and the solid was filtered and dried to obtain the hydrochloride salt of compound 7.
[0168] Characteristic hydrogen signals from NMR of compound 7 hydrochloride:
[0169] 1 HNMR(CD3OD,400MHz)δ: 3.65-3.55(m,3H),3.08-3.00(m,2H),3.00-2.86(m ,4H),2.05-1.98(m,1H),1.97-1.79(m,5H),1.79-1.63(m,5H),1.63-1.55(m ,2H),1.50-1.38(m,6H),1.38-1.23(m,12H),1.23-1.05(m,6H),1.03-0.99 (m,1H),0.97(d,J=6.5Hz,3H),0.94(s,3H),0.93-0.86(m,3H),0.69(s,3H);
[0170] Mass spectrometry data of compound 7 hydrochloride:
[0171] ESI-MS m / z: 532.01 [M+1] +
[0172] Comparative Example 5: Preparation of Compound 8
[0173] 1. Preparation of Compound 8
[0174] Compound 8 has the following structure:
[0175] Compound 8 was prepared by referring to the preparation method of compound 1 in Example 1, except that allodeoxycholic acid was replaced with commercially available cholic acid (CAS: 81-25-4).
[0176] 2. Preparation of Compound 8 Hydrochloride
[0177] Compound 8, prepared according to the above method, was dissolved in methyl tert-butyl ether, and hydrochloric acid gas was passed through it. A white solid precipitated out, and the solid was filtered and dried to obtain the hydrochloride salt of compound 8.
[0178] Mass spectrometry data of compound 8 hydrochloride:
[0179] ESI-MS m / z: 678.03 [M+1] +
[0180] HPLC analysis conditions: HILIC column as stationary phase, 60% methanol / 40% 0.1% trifluoroacetic acid aqueous solution as mobile phase, and differential refractive index detector. HPLC results showed that the purity of the above compounds was >98%.
[0181] The following experimental examples demonstrate the beneficial effects of the present invention. Similar to the Ceragenins-type compounds reported in the literature, the non-salt compounds of the present invention are oily, which is not conducive to practical application, while most of their salt-forming compounds are solid. Therefore, compounds 1-8 in the experimental examples of the present invention were all prepared and implemented using solid hydrochloride salts.
[0182] Experimental Example 1: In vitro inhibitory activity of the compound of the present invention against a variety of bacteria (18±2 hours of incubation)
[0183] 1. Test Methods
[0184] After thawing, the bacterial strains (using *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Candida albicans*, and *Escherichia coli*, respectively) were streaked on MH agar plates and cultured for 18-24 hours. Colonies were picked and diluted in MH broth to a concentration of 0.5 McFarland. Compounds 1-8 (test compounds) prepared in Examples 1-7 and Comparative Example 1 were dissolved in an appropriate amount of DMSO and diluted with MH broth. The initial concentration of the test compound was set at 256 μg / ml, with 10 serial dilutions (two-fold). The bacterial suspension and MH broth containing the test compound were inoculated at a 1:1 ratio into 96-well plates, with a total volume of 200 μl, and incubated at 37°C for 16-20 hours. The liquid from the clear wells (wells where the culture medium was clear) was inoculated into MH agar plates and incubated at 37°C for 24 hours. Because the compound solution is absorbed by the agar, if the bacteria are not killed by the compound, they will grow and form colonies in the absence of compound inhibition. Therefore, the minimum concentration at which no bacterial colonies grow can be considered the minimum bactericidal concentration (MBC) of a compound.
[0185] 2. Test Results
[0186] The minimum bactericidal concentrations (MBCs) of compounds 1-8 against each bacterial strain are recorded in Table 1 below:
[0187] Compounds with an MBC value >100 μg / ml are considered +, those between 10 and 100 μg / ml are considered ++, and those <10 μg / ml are considered +++.
[0188] Table 1. Minimum bactericidal concentrations (MBC) of compounds 1-8 against various bacterial strains.
[0189] As shown in the antibacterial assay at 18±2 hours, compound 8 exhibited strong antibacterial and bactericidal activity, which is basically consistent with the literature reports. Based on MBC concentration analysis, among the multiple structural analogs (i.e., compounds 1-7), compounds 1, 2, 4, and 6 showed the most prominent activity.
[0190] This invention investigated the disinfection activity of compounds 1-8 through subsequent experimental examples. First, the neutralizing agent was determined according to the provisions of the "Disinfection Technical Specifications (2002 Edition)". A neutralizing agent is a reagent used to eliminate residual disinfectant on the surface of test microorganisms in a suspension of the test microorganism and disinfectant, thereby rendering the microorganisms inactive and inactivating. D / E neutralized broth can be used as a neutralizing agent for compounds 1-8.
[0191] Experimental Example 2: Quantitative killing test of the weakly acidic disinfectant compound of the present invention against Escherichia coli and Pseudomonas aeruginosa within 1 minute.
[0192] I. Quantitative bactericidal test of the disinfectant of this invention against Escherichia coli
[0193] 1. Preparation of Escherichia coli (8099) suspension:
[0194] Take a lyophilized tube of *E. coli* culture, open it under aseptic conditions, and add an appropriate amount of nutrient broth using a capillary pipette. Gently pipette several times to dissolve and disperse the culture. Take a test tube containing 10.0 ml of nutrient broth, add a small amount of the culture suspension, and incubate at 37°C for 18–24 hours. Use an inoculation loop to take the first-generation culture suspension and streak it onto a nutrient agar plate, incubating at 37°C for 18–24 hours. Pick typical colonies from the second-generation culture and inoculate them onto a nutrient agar slant, incubating at 37°C for 18–24 hours to obtain the third-generation culture. Take fresh culture from nutrient agar slant culture of the bacterial strain at generations 3-14 (each generation incubated for 18-24 hours). Using a 5.0 ml pipette, add 3.0 ml-5.0 ml of diluent (tryptone physiological saline solution; the same diluent is used for all subsequent dilution procedures) to the slant tube, and repeatedly pipette to wash away the bacterial growth. Then, using a 5.0 ml pipette, transfer the washings to another sterile test tube and mix (shake) with an electric mixer for 20 seconds to ensure uniform bacterial suspension. The initially prepared bacterial suspension should first be roughly determined using a bacterial turbidimetric assay, and then diluted with the diluent to approximately 5 × 10⁻⁶. 8 The concentration of cfu / ml should be maintained, and the bacterial vegetative suspension should be stored in a refrigerator at 4°C for later use. It should not be left overnight before use.
[0195] 2. Experimental Groups:
[0196] The experiment was divided into a test group with disinfectant added, a control group with diluent instead of disinfectant, and a blank group without E. coli inoculation. The blank group was used to monitor whether the culture medium was contaminated by other microorganisms.
[0197] 3. Disinfectant preparation:
[0198] Accurately weigh the hydrochloride salts of compounds 1-8 prepared according to the methods described in the examples and control examples, and directly dilute them with neutral sterile water to 1.25 times the test concentration, i.e., 1.25 mg / ml (according to section 2.1.1.7 of the "Disinfection Technical Specifications 2002", since the bacterial solution and test solution need to be mixed at a ratio of 1:4 during the operation, the test solution should be prepared at 1.25 times the test concentration, so that the final concentration after dilution is 1.0 mg / ml. The following experimental examples are prepared in the same principle). The solutions prepared with the hydrochloride salts of the above compounds are all weakly acidic as measured by a pH meter, with a pH range of 4.5 to 6.5. The prepared disinfectant is placed in a water bath at 20℃±1℃ for later use.
[0199] 4. Experimental Procedure:
[0200] Take the E. coli suspension obtained in step 1, with a concentration of approximately 5 × 10⁻⁶. 8 CFU / ml. For the disinfection test, use a sterile large test tube. First, add 0.5 ml of E. coli suspension, then add 0.5 ml of organic interfering substance (3% BSA solution), mix well, and incubate in a 20℃±1℃ water bath for 5 minutes. Then, use a sterile pipette to add 4.0 ml of the disinfectant obtained in step 3 above, mix quickly, and start timing immediately. After the E. coli and disinfectant have interacted for 1 minute, add 0.5 ml of the E. coli and disinfectant mixture to 4.5 ml of sterilized neutralizing agent and mix well. After the E. coli and disinfectant mixture has reacted with the neutralizing agent for 10 minutes, take 1.0 ml of the sample solution and determine the number of viable bacteria using the viable bacteria culture counting method. Inoculate two petri dishes with each sample solution. If the number of colonies growing on the plates is high, perform a series of 10-fold dilutions before viable bacteria culture counting. Simultaneously, use the diluted solution instead of the disinfectant for parallel tests as a control group; use the diluted solution instead of the bacterial suspension for parallel tests as a blank group. All test samples were incubated at 37℃ for 48 hours, and the final results were observed. The experiment was repeated three times, and the viable bacterial concentration (cfu / ml) of each group was calculated and converted to logarithmic value (N). Then, the kill log value was calculated using the following formula:
[0201] Log kill count (KL) = Logarithm of average viable bacterial concentration in the control group (No) - Logarithm of viable bacterial concentration in the experimental group (Nx)
[0202] Kill rate = (Average viable bacterial concentration in control group - Viable bacterial concentration in test group) / (Average viable bacterial concentration in control group) * 100%
[0203] Table 2 shows the 1-minute bactericidal effect of the weakly acidic compound disinfectant on Escherichia coli.
[0204] II. Quantitative bactericidal test of the disinfectant of this invention against Pseudomonas aeruginosa
[0205] The quantitative killing effect of disinfectant on Escherichia coli was tested using the same method as described above, except that Escherichia coli was replaced with Pseudomonas aeruginosa.
[0206] Table 3 shows the 1-minute killing effect of weakly acidic compound disinfectants on Pseudomonas aeruginosa.
[0207] In summary, the experimental results are shown in Table 2-3. Under the same conditions, compounds 3, 5, and 7 failed to meet the acceptable limits for the killing of *Escherichia coli* and *Pseudomonas aeruginosa*, with compound 7 exhibiting the worst bactericidal effect. The remaining compounds (i.e., compounds 1, 2, 4, 6, and 8) all met the acceptable limits.
[0208] Experimental Example 3: Quantitative killing test of the weakly acidic disinfectant compound of the present invention against Staphylococcus aureus and Candida albicans within 1 minute.
[0209] I. Quantitative Killing Test of Staphylococcus aureus
[0210] 1. Preparation of Staphylococcus aureus (ATCC6538) suspension:
[0211] The method for preparing Staphylococcus aureus suspension is the same as that for preparing Escherichia coli suspension in Experiment Example 2.
[0212] 2. Disinfectant preparation:
[0213] Compounds 1-8 hydrochlorides were prepared directly with sterile water to a concentration 1.25 times the test concentration, i.e., 12.5 mg / ml (the test concentration is the final concentration after dilution with the bacterial solution, which is 10 mg / ml), with a pH range of 4.5–6.5. The prepared disinfectant was then placed in a water bath at 20℃±1℃ for later use.
[0214] The experimental grouping and procedures were the same as described in Experiment 2, and the results are shown in Table 4:
[0215] Table 4 shows the 1-minute bactericidal effect of the weakly acidic compound disinfectant on Staphylococcus aureus.
[0216] II. Quantitative Killing Test of Candida albicans
[0217] 1. Preparation of Candida albicans (ATCC10231) suspension:
[0218] Take a lyophilized bacterial culture tube, open it aseptically, and add an appropriate amount of Saburg liquid culture medium to the tube using a capillary pipette. Gently pipette several times to thaw and disperse the bacteria. Take a test tube containing 10.0 ml of Saburg liquid culture medium, add a small amount of bacterial suspension, and incubate at 37°C for 18-24 hours. Use an inoculation loop to take the bacterial suspension from the first generation culture and streak it onto a Saburg agar plate, incubating at 37°C for 18-24 hours. Pick typical colonies from the above second generation culture and inoculate them onto a Saburg agar slant, incubating at 37°C for 18-24 hours to obtain the third generation culture. Seal and store at 4°C for no more than 6 weeks. During the experiment, use the third generation slant culture to continuously subculture on Saburg agar slants, following the same method as the third generation. Take fresh culture (18-24 hours) from a 6th generation Sabouraud agar slant. Using a 5.0 ml pipette, add 3.0-5.0 ml of diluent to the slant tube and repeatedly pipette to wash away the bacterial growth. Then, using a 5.0 ml pipette, transfer the washings to another sterile tube and mix with an electric mixer for 20 seconds to ensure the Candida albicans bacteria are evenly suspended. Dilute with the diluent to a bacterial count of approximately 5 × 10⁻⁶. 8 CFU / ml, store at 4℃ for later use, do not keep overnight.
[0219] 2. Disinfectant preparation:
[0220] Compounds 1-8 hydrochlorides were all prepared directly with neutral sterile water to a concentration 1.25 times the test concentration, i.e., 12.5 mg / ml (the test concentration is the final concentration after dilution with the bacterial solution, which is 10 mg / ml), with a pH range of 4.5–6.5. The pH of compound 2 hydrochloride was determined to be 5.5. The prepared disinfectant was placed in a water bath at 20℃±1℃ for later use.
[0221] 3. Experimental Procedures:
[0222] Take the Candida albicans suspension obtained in step 1, with a concentration of approximately 5 × 10⁻⁶. 8CFU / ml. Take a sterile large test tube, first add 0.5 ml of Candida albicans suspension, then add 0.5 ml of organic interfering substance (3% BSA solution), mix well, and place in a 20℃±1℃ water bath for 5 min. Then, use a sterile pipette to inject 4.0 ml of the disinfectant obtained in step 2 into the tube, mix quickly, and start timing immediately. After the test bacteria (i.e., Candida albicans) interact with the disinfectant for 1 min, add 0.5 ml of the test bacteria and disinfectant mixture to 4.5 ml of sterilized neutralizing agent and mix well. After each tube of test bacteria and disinfectant mixture has reacted with the neutralizing agent for 10 min, take 1.0 ml of the sample solution and determine the number of viable bacteria according to the viable bacteria culture counting method. Inoculate two petri dishes with each sample solution using Saburg dextrose agar as the culture medium. If the number of colonies growing on the plate is large, serial 10-fold dilutions can be performed before viable bacteria culture counting. Simultaneously, a diluent was used instead of disinfectant in parallel experiments as a control group; a diluent was used instead of bacterial suspension in parallel experiments as a blank group. All test samples were cultured in a 37℃ incubator, and the vegetative cells were cultured for 48 hours to observe the final results. The experiment was repeated three times, and the viable bacterial concentration (cfu / ml) of each group was calculated and converted to a logarithmic value (N). Then, the logarithmic kill value was calculated using the following formula:
[0223] Log kill count (KL) = Logarithm of average viable bacterial concentration in the control group (No) - Logarithm of viable bacterial concentration in the experimental group (Nx)
[0224] Kill rate = (Average viable bacterial concentration in control group - Viable bacterial concentration in test group) / (Average viable bacterial concentration in control group) * 100%
[0225] The average number of kills and the average kill rate are the average of three replicates.
[0226] Table 5. Killing effect of weakly acidic compound disinfectants on Candida albicans within 1 minute.
[0227] The results are shown in Tables 4-5. When the pH of the disinfectant is weakly acidic, even when the concentration of compounds 1-8 is prepared at 10 mg / ml, none of them showed a satisfactory bactericidal effect against Staphylococcus aureus and Candida albicans. Under the same conditions, the bactericidal activities of each compound showed significant differences, with compounds 1 and 2 showing the best bactericidal effect.
[0228] Considering the aforementioned non-compliance, the concentrations of compounds 6 and 8, as reported in the literature, were increased from 10 mg / ml to 20 mg / ml, and the 1-minute killing effect against Candida albicans was tested again. The preparation method was as described above, using neutral sterile water; the disinfectant solutions prepared from the hydrochlorides of compounds 6 and 8 were both weakly acidic.
[0229] Table 6 shows the 1-minute killing effect of increased concentrations of compounds 6 and 8, weakly acidic disinfectants, on Candida albicans.
[0230] The results are shown in Table 6. Even when the concentration of Ceragenins 6 and 8, previously reported in the literature, was increased from 10 mg / ml to 20 mg / ml, they still failed to achieve a 1-minute kill effect against Candida albicans. Furthermore, a two-fold increase in concentration did not significantly improve the kill rate or logarithmic kill value. The 20 mg / ml concentration was already far higher than the aforementioned MBC values (for example, the MBC values of compounds 6 and 8 in the 18±2 hour antibacterial test described in Experimental Example 1 were both <0.1 mg / ml).
[0231] This invention is the first to discover that the pH conditions for preparing disinfectants are extremely crucial for the 1-minute killing effect of Staphylococcus aureus and Candida albicans. The following experimental example, using compound 2 as an example, systematically studies the killing effect of disinfectants prepared at different pH values.
[0232] Experimental Example 4: Quantitative killing test of compound 2 against Candida albicans / Staphylococcus aureus under different pH conditions (1 min)
[0233] 1. The preparation of the Candida albicans suspension was the same as described in Experimental Example 3.
[0234] 2. Preparation of disinfectant: Prepare phosphate buffer systems containing 5% DMSO, with final pH values of 5.0, 7.0, and 9.0 respectively. Take an appropriate amount of compound 2, dissolve it in each of the three phosphate buffer systems mentioned above, monitor the pH with a pH meter, and adjust it to the above pH values. The compound concentration should be 1.25 times the test concentration, i.e., 12.5 mg / ml.
[0235] Following the operating method described in Experiment Example 3, the disinfectant with compound 2 as the active ingredient at a test concentration of 10 mg / ml under the above three pH conditions was tested for its killing effect on Candida albicans and Staphylococcus aureus. The results were repeated three times and the average value was taken.
[0236] Table 7. Killing effect of compound 2 at different pH values on Candida albicans / Staphylococcus aureus within 1 min.
[0237] The results are shown in Table 7. pH significantly affects the 1-minute killing effect of the disinfectant containing compound 2 of this invention as the active ingredient against Candida albicans and Staphylococcus aureus. At a concentration of 10 mg / ml, the system at pH 5.0 failed to achieve a satisfactory killing effect, but the logarithmic kill count significantly increased with increasing pH. When the pH reached 7.0 and 9.0, the 10 mg / ml concentration of the disinfectant achieved a satisfactory killing effect, and the logarithmic kill count at pH 9.0 was significantly higher than that at pH 7.0.
[0238] The above-mentioned 10 mg / ml Compound 2 disinfectant solutions at different pH values were used to test the killing effect of Escherichia coli and Pseudomonas aeruginosa for 1 minute. It was found that pH had little effect on the killing effect of E. coli and Pseudomonas aeruginosa. At a concentration of 10 mg / ml, regardless of pH 5.0, 7.0, or 9.0, a 100% killing effect was achieved. Furthermore, concentration dilution tests showed that at pH 5.0, 7.0, or 9.0, concentrations as low as 0.02 mg / ml of Compound 1 and Compound 2 could effectively kill E. coli and Pseudomonas aeruginosa within 1 minute.
[0239] The results showed that the pH of the disinfectant solution of the compound of the present invention is very important for killing Staphylococcus aureus and Candida albicans within 1 minute, but has little effect on Escherichia coli and Pseudomonas aeruginosa.
[0240] Experimental Example 5: Quantitative killing test of the compound of the present invention against Staphylococcus aureus / Candida albicans at pH 9.0 for 1 minute.
[0241] 1. The preparation of Staphylococcus aureus suspension and Candida albicans suspension is the same as in Experiment 3.
[0242] 2. Following the study of compound 2 in Experiment 4 and the discovery of its pH effect against Candida albicans, this experiment further compared the activities of compounds 1, 2, 4, 6, and 8 under the same pH conditions. Compounds 3, 5, and 7 showed significantly weaker killing activity against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Candida albicans, making them insufficient for comparison. The disinfectant preparation was the same as in Experiment 4.
[0243] Following the operating method described in Experimental Example 4, the disinfectant effects of the above-mentioned compounds on Staphylococcus aureus and Candida albicans under pH 9.0 conditions were compared.
[0244] Table 8 shows the bactericidal effect of the compounds on Staphylococcus aureus at pH 9.0 for 1 minute.
[0245] Table 9 shows the bactericidal effect of the compounds on Candida albicans at pH 9.0 for 1 minute.
[0246] The results are shown in Tables 8-9: Compounds 1, 2, and 4, at a concentration of 10 mg / ml and pH 9.0, all achieved satisfactory killing effects against Candida albicans and Staphylococcus aureus within 1 minute. Comparing the number of surviving colonies and the number of kill logs, compounds 1 and 2 showed significant killing effects against Staphylococcus aureus and Candida albicans, with an observable colony count of 0, indicating complete eradication of both bacteria. A small number of colonies were still observed with compound 4.
[0247] Compared with the results in Table 5 of Experimental Example 3, when Compounds 6 and 8 at 10 mg / mL adjust the pH value from weakly acidic to 9.0, their 1 min killing activity against Candida albicans is significantly improved. A small number of colonies can still be observed for Compound 8, but it reaches the qualified killing logarithm; Compound 6 is close to qualification.
[0248] Under the condition of pH 9.0, the killing effects of Compound 1 and Compound 2 on Staphylococcus aureus and Candida albicans are significantly better than those of known Compounds 6 and 8, and Compound 4 has equivalent activity to Compound 8.
[0249] Experimental Example 6: 1 min quantitative killing test of disinfectants with different formulation systems of the compounds of the present invention against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Candida albicans
[0250] The above hydrochloride salts of Compounds 1 to 8 are easily soluble in aqueous solutions, but are prone to precipitate when the pH is adjusted to neutral or alkaline. In Experimental Examples 3, 4 and 5, conditions of DMSO-assisted dissolution and phosphate pH adjustment were used to study the pH effect, but DMSO-assisted dissolution is rarely used in the practical application of disinfectants. According to the cosolvents listed in the national standard "GB38850-2020", the present invention selects three cosolvent systems for comparison: hydroxypropyl-β-cyclodextrin, glycerol, and EDTA tetrasodium salt.
[0251] Preparation of disinfectant solution: pentasodium metasilicate is used to adjust the pH value to 8.0, and Compound 1 and Compound 2 are formulated into a concentration of 0.5 mg / mL using three systems, namely 5% glycerol aqueous solution, 5% hydroxypropyl-β-cyclodextrin aqueous solution, and 0.01% EDTA tetrasodium aqueous solution, for the 1 min killing test.
[0252] The operation of the killing test is the same as before. For Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus, an average killing logarithm of ≥5.00 over 3 tests is qualified, and <5.00 is unqualified; for Candida albicans, an average killing logarithm of ≥4.00 over 3 tests is qualified, and <4.00 is unqualified. The test results are shown in Table 10 below:
[0253] Table 10 1 min killing effects of Compounds 1 and 2 in three different formulation systems at pH 8.0
[0254] The results showed that the co-solvent system also affects disinfection activity. Of the three systems, compounds 1 and 2 only achieved satisfactory killing effects against *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Candida albicans* within one minute at concentrations as low as 0.5 mg / ml in the glycerol / sodium metasilicate pentahydrate system. At the same low concentration, the hydroxypropyl-β-cyclodextrin system failed to achieve satisfactory killing effects against any bacteria or fungi; the tetrasodium EDTA system only achieved satisfactory killing effects against *Escherichia coli*, *Pseudomonas aeruginosa*, and *Candida albicans*, but failed to achieve satisfactory killing effects against *Staphylococcus aureus*. The specific mechanism by which these co-solvents cause differences in activity remains unclear.
[0255] Experimental Example 7: Quantitative killing test of Compound 2 against Candida albicans / Staphylococcus aureus under different concentrations / pH conditions for 1 minute
[0256] This experiment further explores the bactericidal effect of compound 2 against Candida albicans and Staphylococcus aureus under different concentrations / pH conditions, using glycerol as a co-solvent and sodium metasilicate pentahydrate as a pH adjuster. The experimental procedure is the same as in Experiment 3, and the average value of three repeated tests is used as the standard. A logarithmic kill value of ≥4.00 for Candida albicans and ≥5.00 for Staphylococcus aureus is considered acceptable.
[0257] Table 11. Killing effect of compound 2 on Candida albicans at different pH / concentrations for 1 min.
[0258] Table 12 Results of Compound 2's 1-min inactivation of Staphylococcus aureus at different pH / concentrations
[0259] The results are shown in Tables 11-12, which once again prove that pH has a significant impact on the killing effect.
[0260] Against Candida albicans, even at a concentration as high as 12.5 mg / ml, compound 2 failed to meet the acceptable standard at pH 6.5. Under neutral conditions at pH 7.0, the minimum bactericidal concentration was 2.5 mg / ml. The bactericidal effect was comparable at pH 7.5, 8.0, 8.5, and 9.0, with a minimum bactericidal concentration of 0.1 mg / ml. A pH ≥ 7 is an important parameter for the bactericidal system using compound 2 of this invention as the active ingredient.
[0261] Against Staphylococcus aureus, even at a concentration as high as 12.5 mg / ml, compound 2 failed to meet the acceptable standard at pH 6.5. At a neutral pH of 7.0, the minimum effective concentration was 0.5 mg / ml. At pH 8.0, 8.5, and 9.0, the bactericidal effect was comparable, with a minimum effective concentration of 0.1 mg / ml. The study found that when the pH was further increased to 11, the compound's effectiveness in killing Candida albicans or Staphylococcus aureus within 1 minute was also comparable.
[0262] The results showed that both the concentration of the compound and pH affected the killing effect, but pH ≥ 7 was an extremely important condition to ensure that the disinfectant was qualified to kill the virus.
[0263] Experimental Example 8: Antibacterial activity test of compound 8 under different pH conditions (18±2 hours)
[0264] This experimental example uses compound 8, which has been reported in the literature, to investigate whether pH affects the antibacterial or bactericidal effect of Ceragenins-like compounds after 18±2 hours.
[0265] The experimental method was the same as in Experiment 1. After co-incubating the bacterial suspension (Candida albicans) with Compound 8 under different pH conditions for 18±2 hours, the MBC (minimum bactericidal concentration) was determined. Compound 8 at different concentration gradients and pH values was prepared using a glycerol / sodium metasilicate pentahydrate system (a small amount of dilute hydrochloric acid was used to adjust the pH for acidic conditions).
[0266] MBC values >100 μg / ml are +, 10-100 μg / ml are ++, and <10 μg / ml are +++.
[0267] Table 13 Results of Compound 8 in killing Candida albicans under different pH conditions for 18±2 hours
[0268] The results are shown in Table 13. When the compound and bacterial solution were incubated for a sufficiently long time (18 ± 2 hours), the effect of pH on MBC was not significant. In summary, the results of the aforementioned experiments indicate that pH affects the short-term killing rate of the compound; once the compound and bacterial solution are incubated for a sufficiently long time, the killing effects at different pH values tend to converge. However, as mentioned earlier, the killing time is extremely important for the application of disinfectants, and the effect of pH becomes very significant.
[0269] Experimental Example 9: Bacillus subtilis var. niger spore-killing test
[0270] 1. Preparation of Bacillus subtilis var. niger spore suspension (ATCC9372):
[0271] Take a lyophilized bacterial culture tube, open it under aseptic conditions, and add an appropriate amount of nutrient broth medium using a capillary pipette. Gently pipette several times to dissolve and disperse the bacteria. Take a test tube containing 10 ml of nutrient broth medium, add a small amount of bacterial suspension, and incubate at 37°C for 18-24 hours. Use an inoculation loop to take the bacterial suspension from the first generation culture and streak it onto a nutrient agar plate, incubating at 37°C for 18-24 hours. Pick typical colonies from the above second generation culture, inoculate them onto nutrient broth medium, and incubate at 37°C for 18-24 hours to obtain the third generation culture. Using a 10.0 ml pipette, take 5.0 ml to 10.0 ml of 18-24 h nutrient broth culture from generations 3-5 and inoculate it onto the surface of nutrient agar medium in a Rohler flask. Shake the flask to ensure the bacterial culture covers the entire surface of the agar medium. Remove any excess broth culture. Place the Rohler flask in a 37°C incubator for 5-7 days. Using an inoculation loop, take a small amount of the bacterial sample and smear it onto a glass slide. Fix the slide and stain it using a modified spore staining method. Examine the slide under a microscope (oil immersion). When the spore formation rate reaches 95% or higher, proceed with the following treatment. Otherwise, continue to incubate at room temperature for a certain period until the above spore formation rate is achieved before proceeding with the following treatment.
[0272] Add 10.0 ml of sterile distilled water to each Roche flask using a 10.0 ml pipette, and gently scrape off the bacterial growth with an L-shaped rod. Aspirate the first batch of washed bacterial suspension, then add another 5.0 ml of sterile distilled water to the flask and repeat the washing process. Combine the first and second batches of washed bacterial suspension in a sterile Erlenmeyer flask containing glass beads, shake for 5 minutes to break up the bacterial clumps and create a homogeneous spore suspension. If necessary, place the Erlenmeyer flask containing the bacterial suspension in a 45°C water bath for 24 hours to allow the bacteria to autolyze and break down into individual spores. Filter the spore suspension with sterile cotton or gauze to remove any agar clots. Place the filtered spore suspension in a sterile centrifuge tube and centrifuge at 3000 rpm for 30 minutes. Discard the supernatant and add distilled water to resuspend the spores. Repeat the centrifugation and resuspension washing process three times. Suspend the washed spores in distilled water in an Erlenmeyer flask and add an appropriate amount of small glass beads. Place the spore-forming solution in an 80°C water bath for 10 minutes (or 60°C for 30 minutes) to kill any remaining vegetative bacteria. After cooling to room temperature, store in a 4°C refrigerator for later use. The shelf life is six months.
[0273] 2. Experimental Groups:
[0274] The experiment was divided into a test group with added disinfectant, a control group with diluted disinfectant instead of disinfectant, and a blank group without inoculation with Bacillus subtilis var. niger spores.
[0275] 3. Disinfectant preparation:
[0276] The disinfectant used was a 5% glycerol / sodium metasilicate pentahydrate aqueous solution system (i.e., a system obtained by adding sodium metasilicate pentahydrate to an aqueous solution containing 5% glycerol by mass and adjusting it to the target pH value), with a pH value of 8.0. The compounds were compounds 1 and 2 of this invention, prepared at 1.25 times the test concentration, i.e., 12.5 mg / ml, and the killing effect was tested under the conditions of 15 min, 30 min, and 45 min.
[0277] 4. Experimental procedure: Refer to Experiment Example 2 for the procedure.
[0278] 5. Experimental Results:
[0279] Table 14. Killing effect of the compounds of the present invention on Bacillus subtilis var. niger spores within 45 min.
[0280] The results are shown in Table 14. When the disinfectants of compounds 1 and 2 were applied for 15 min, 30 min and 45 min respectively, the log killing values of Bacillus subtilis var. niger spores were ≥5.00, which met the technical specifications for high-efficiency disinfection.
[0281] Experimental Example 10: LD50 of compounds 1, 2 and 8 of the present invention 50 Testing and Experiment
[0282] The LD values of compounds 1, 2, and 8 were tested according to the description method in section 2.3.1 of the "Disinfection Technical Specifications 2002". 50 value.
[0283] 1. Laboratory animals:
[0284] Eighty Balb / c mice, half male and half female, 6 weeks old, weighing 18-22g, were randomly divided into 18 groups after one week of acclimatization feeding. These groups corresponded to six dosage groups for each of compounds 1, 2, and 8, with corresponding dosages of 200mg / kg, 250mg / ml, 300mg / kg, 350mg / kg, 400mg / kg, and 450mg / kg, respectively.
[0285] 2. Experimental Procedure:
[0286] Before the experiment, animals in each group were fasted overnight, but water was allowed. The test compounds were dissolved in a 5% hydroxypropyl-β-cyclodextrin aqueous solution to prepare six concentrations corresponding to six dosage groups: 40 mg / ml, 50 mg / ml, 60 mg / ml, 70 mg / ml, 80 mg / ml, and 90 mg / ml. Each mouse was administered a single oral gavage dose of 50 μl / 10 g body weight. After administration of the compounds, animals in each group were fed normally and observed for 14 days. During this period, the signs of poisoning, the number of deaths, and the time of death were observed and recorded. All remaining animals were euthanized at the end of the experiment. Animals that died during the observation period and those ultimately euthanized were immediately dissected for visual inspection for any abnormal organs or tissues. The LD50 of compounds 1, 2, and 8 was calculated. 50 .
[0287] The experimental results are shown in Table 15 below:
[0288] Table 15 Results of drug administration in each group of experimental animals
[0289] Calculate the LD values of the three compounds using the probabilistic unit-logarithmic graphical method. 50 Based on the mortality rates of each group of animals, the probability units for each group were retrieved from Table 16. The probability units for mortality rates of 0% and 100% were retrieved from Table 17. The mortality rates and corresponding probability indices for different doses of the three compounds are shown in Table 18 below.
[0290] Table 16 Percentage-Probability Unit Conversion Table Note: The horizontal headings represent the single-digit figures of the mortality rate, and the vertical headings represent the tens-digit figures of the mortality rate.
[0291] Table 17 Probability units for reaction rates of 0% and 100%
[0292] Table 18 Mortality rates and corresponding probability indices for different doses of compounds 1, 2, and 8.
[0293] Based on the results in Table 18, a scatter plot was plotted, with the horizontal axis representing the logarithmic dose (X) and the vertical axis representing the probability unit (Y). A straight line was fitted, and the logarithmic dose corresponding to a probability unit of 5 was taken from the line; its antilogarithm is the LD. 50 According to the "Disinfection Technical Specifications 2002", the mortality rate of animals in the highest dose group should generally be ≥90%, and the mortality rate of animals in the lowest dose group should be ≤10%. Therefore, the data for the 200 mg / kg group of compound 1, the 200 mg / kg group of compound 2, and the 450 mg / kg group of compound 8 in Table 18 do not meet the requirements and are not included in the scatter plot. mg / kg is equivalent to mpk.
[0294] The dose-probability unit scatter plots for compounds 1, 2, and 8 are shown in Figures 1, 2, and 3, respectively. The calculated LD50 of compound 1 is... 50 The LD50 of compound 2 is 338.4 mg / kg. 50 The LD value is 363.3 mg / kg, and the LD value of compound 8 is... 50 The value was 305.1 mg / kg.
[0295] The experimental results show that the LD values of compounds 1 and 2 are... 50 Value greater than LD of compound 8 50 Value, and from the test compound LD 50 In the tests, it was also observed that, at the same dosage, compounds 1 and 2 had less toxicity than compound 8. This indicates that compounds 1 and 2 are safer than compound 8, especially compound 2, which is safer and less toxic.
[0296] In summary, the compounds of this invention can effectively kill *Escherichia coli* and *Pseudomonas aeruginosa*, and achieve a satisfactory 1-minute kill effect against *Staphylococcus aureus* and *Candida albicans* under neutral and alkaline conditions. This invention also marks the first discovery that compounds 1 and 2 can achieve highly efficient disinfection effects against spores in a short time, meeting the national technical standards for high-efficiency disinfection (Disinfection Technical Specifications (2002 edition)). Compounds 1 and 2 of this invention have higher oral gavage safety compared to the prior art compound 8. Therefore, the compounds of this invention and their salts have broad application prospects in practical disinfection applications.
Claims
1. A cholesteric compound or a salt thereof, characterized by, The cholesteric compound has a structure as shown in Formula I, Formula II, or Formula III:
2. The cholesteric compound or salt thereof according to claim 1, wherein The salt is hydrochloride, glucuronide, acetate, butyrate, or 1,5-naphthalenedisulfonate.
3. A process for preparing the cholesteric compound of claim 1, characterized by, The method includes the following steps: (1) Bile acid compounds react with haloalkenes under alkaline conditions to give intermediate 1; (2) Intermediate 1 reacts with an amine to give intermediate 2; (3) Intermediate 2 undergoes a hydroboration-oxidation reaction to obtain intermediate 3; (4) Intermediate 3 first reacts with a sulfonating agent to generate a sulfonate ester, and then reacts with a nucleophile under alkaline conditions to obtain intermediate 4; (5) Intermediate 4 is hydrolyzed under acidic conditions and reacts with a reducing agent to obtain the cholesteric compound; wherein, when the cholic acid compound is allocholic acid, the intermediate 1 is When the amine is octylamine, intermediate 2 is Intermediate 3 is Intermediate 4 is The cholesteric compound is When the cholic acid compound is hyodeoxycholic acid, the intermediate 1 is When the amine is octylamine, intermediate 2 is Intermediate 3 is Intermediate 4 is The cholesteric compound is When the cholic acid compound is hyodeoxycholic acid, intermediate 1 is When the amine is laurylamine, intermediate 2 is Intermediate 3 is Intermediate 4 is The cholesteric compound is 4. The method of claim 3, wherein, The cholic acid compound mentioned in step (1) is allocodeoxycholic acid or porcine deoxycholic acid; The amine mentioned in step (2) is octylamine or laurylamine; The borohydride-oxidizing agent mentioned in step (3) is 9-boronbicyclo[3.3.1]nonane and H2O2; The sulfonating agent in step (4) is chloride methanesulfonate, and the nucleophile is bis(tert-butyloxycarbonyl)amine; The reducing agent in step (5) is borane.
5. A disinfectant characterized by, The disinfectant is a formulation prepared using the cholesteric compound or its salt as the active ingredient according to claim 1, and the pH of the disinfectant is ≥7.
0.
6. The disinfectant of claim 5, wherein The disinfectant also includes solvents, disinfectant-acceptable cosolvents, and pH adjusters.
7. The disinfectant of claim 6, wherein, The solvent is water, the co-solvent is glycerol, and the pH adjuster is at least one of ethylenediaminetetraacetic acid tetrasodium, sodium metasilicate pentahydrate, sodium phosphate, and sodium carbonate.
8. The use of the compound of claim 1 or its salt or the disinfectant of any one of claims 5 to 7 in the preparation of disinfection products for the disinfection of mucous membranes and skin, hands, feet, medical devices and supplies, textiles, food (drinking) utensils, drinking water and swimming pool water, fruits and vegetables.
9. The use of the compound of claim 1 or its salt or the disinfectant of any one of claims 5 to 7 in the preparation of a disinfectant product that kills at least one of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Bacillus subtilis var. niger spores.
10. A method for disinfecting mucous membranes and skin, hands, feet, medical devices and supplies, fabrics, food (drinking) utensils, drinking water and swimming pool water, fruits and vegetables using the compound of claim 1 or its salt or any one of claims 5 to 7.
